# Hoog-dosis versus standaarddosis griepvaccin en mortaliteit bij ouderen: JAMA

*geplaatst 2021-01-05 · Hartfalen · JAMA · doi 10.1001/jama.2020.23649 · https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/*

JAMA trial die hoog-dosis versus standaarddosis griepvaccin vergeleek op mortaliteit en cardiopulmonale hospitalisatie bij ouderen.

## English: Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

This JAMA trial comparing high-dose trivalent with standard-dose quadrivalent influenza vaccine on cardiovascular-related outcomes in elderly patients explored whether enhanced immunogenicity translates to cardiovascular protection in the highest-risk population.

## Abstract (original, from the publication)

IMPORTANCE: Influenza is temporally associated with cardiopulmonary morbidity and mortality among those with cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been associated with reduced risk of influenza illness. OBJECTIVE: To evaluate whether high-dose trivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine would reduce all-cause death or cardiopulmonary hospitalization in high-risk patients with cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic multicenter, double-blind, active comparator randomized clinical trial conducted in 5260 participants vaccinated for up to 3 influenza seasons in 157 sites in the US and Canada between September 21, 2016, and January 31, 2019. Patients with a recent acute myocardial infarction or heart failure hospitalization and at least 1 additional risk factor were eligible. INTERVENTIONS: Participants were randomly assigned to receive high-dose trivalent (n = 2630) or standard-dose quadrivalent (n = 2630) inactivated influenza vaccine and could be revaccinated for up to 3 seasons. MAIN OUTCOMES AND MEASURES: The primary outcome was the time to the composite of all-cause death or cardiopulmonary hospitalization during each enrolling season. The final date of follow-up was July 31, 2019. Vaccine-related adverse events were also assessed. RESULTS: Among 5260 randomized participants (mean [SD] age, 65.5 [12.6] years; 3787 [72%] men; 3289 [63%] with heart failure) over 3 influenza seasons, there were 7154 total vaccinations administered and 5226 (99.4%) participants completed the trial. In the high-dose trivalent vaccine group, there were 975 primary outcome events (883 hospitalizations for cardiovascular or pulmonary causes and 92 deaths from any cause) among 884 participants during 3577 participant-seasons (event rate, 45 per 100 patient-years), whereas in the standard-dose quadrivalent vaccine group, there were 924 primary outcome events (846 hospitalizations for cardiovascular or pulmonary causes and 78 deaths from any cause) among 837 participants during 3577 participant-seasons (event rate, 42 per 100 patient-years) (hazard ratio, 1.06 [95% CI, 0.97-1.17]; P = .21). In the high-dose vs standard-dose groups, vaccine-related adverse reactions occurred in 1449 (40.5%) vs 1229 (34.4%) participants and severe adverse reactions occurred in 55 (2.1%) vs 44 (1.7%) participants. CONCLUSIONS AND RELEVANCE: In patients with high-risk cardiovascular disease, high-dose trivalent inactivated influenza vaccine, compared with standard-dose quadrivalent inactivated influenza vaccine, did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations. Influenza vaccination remains strongly recommended in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02787044.

Auteurs: Orly Vardeny, KyungMann Kim, Jacob A Udell, Jacob Joseph, Akshay S Desai, Michael E Farkouh, Sheila M Hegde, Adrian F Hernandez, Allison McGeer, H Keipp Talbot, Inder Anand, Deepak L Bhatt, Christopher P Cannon, David DeMets, J Michael Gaziano, Shaun G Goodman, Kristin Nichol, Matthew C Tattersall, Jonathan L Temte, Janet Wittes, Clyde Yancy, Brian Claggett, Yi Chen, Lu Mao, Thomas C Havighurst, Lawton S Cooper, Scott D Solomon

---
Bron: JAMA, https://doi.org/10.1001/jama.2020.23649. Bijgewerkt 2026-07-03T13:28:07Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.